Skip to main content
. 2014 Feb 20;2014:935474. doi: 10.1155/2014/935474

Figure 1.

Figure 1

Factors associated with increased risk of bleeding with rivaroxaban [2]. *Care is to be taken in patients receiving concomitant systemic treatment with these agents and rivaroxaban. Rivaroxaban is not recommended in patients receiving concomitant systemic treatment with these agents. ASA = acetylsalicylic acid; CrCl = creatinine clearance; CYP3A4 = cytochrome P450. 3A4; HIV = human immunodeficiency virus; NSAID = nonsteroidal anti-inflammatory drug; VKA = vitamin K antagonist.